Tisotumab Vedotin Shows Superior Efficacy in Recurrent Cervical Cancer Treatment, reveals research

• Progression-free survival was also significantly longer with tisotumab vedotin (4.2 months vs. 2.9 months, HR 0.67, 95% CI 0.54-0.82, P<0.001).

• The confirmed objective response rate was 17.8% with tisotumab vedotin versus 5.2% with chemotherapy (OR 4.0, 95% CI 2.1-7.6, P<0.001).

• Adverse events were common in both groups, occurring in over 98% of patients, with grade 3 or greater events reported in 52.0% of the tisotumab vedotin group and 62.3% of the chemotherapy group.

• Approximately 14.8% of patients discontinued tisotumab vedotin due to treatment-related toxic effects.

In conclusion, the study highlights the superior efficacy of tisotumab vedotin over standard chemotherapy in treating recurrent cervical cancer. The findings underscore its potential as a valuable treatment option in later lines of therapy, offering improved survival outcomes and a higher objective response rate.

Reference:

Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., Lee, J.-Y., Banerjee, S., Maluf, F. C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso, L., Woelber, L., Westermann, A., Covens, A., Hasegawa, K., Kim, B.-G., Raimondo, M., … Slomovitz, B. M. (2024). Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. The New England Journal of Medicine, 391(1), 44–55. https://doi.org/10.1056/nejmoa2313811